US5004593A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hexamethylmelamine formulation exhibiting reduced neurotoxicity
Assignee: Mayo Foundation for Medical Education and Research
•
Filing: 1989-04-17
•
Granted: 1991-04-02
•
Expires: 2009-04-17
Abstract
Abstract A method is provided for reducing the side effects of chemotherapy with hexamethylmelamine (HMM) comprising intravelously administering a stabilized solution of HMM in an aqueous lipid dispersion, so that the central nervous system toxicity associated with oral HMM administration is reduced or eliminated.
Inventors
- 👤 Matthew M. Ames
- 👤 John S. Kovach
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 15:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/33; A61K31/395; A61K31/53; A61K31/66; A61K31/675; A61K33/00; A61K33/24; A61K33/243; A61K47/00; A61K47/06; A61K47/24; A61K47/44; A61K9/00; A61K9/0012; A61K9/0019
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
76 words
A method for reducing the peripheral neuropathy associated with chemotherapy with hexamethylmelamine comprising intravenously administering a stabilized solution of an effective antineoplastic amount of hexamethyl-melamine (HMM) to a cancer patient in need thereof; wherein said HMM is dissolved in an aqueous emulsion comprising about 2-20% of an edible oil; about 0.1-7% of a phosphatide and about 1-10% glycerol, so that peripheral neuropathy is reduced from that observed when the same amount of HMM is orally administered.
Claim 2
Independent Claim
76 words
A method for reducing the peripheral neuropathy associated with chemotherapy with hexamethylmelamine comprising intravenously administering a stabilized solution of an effective antineoplastic amount of hexamethyl-melamine (HMM) to a cancer patient in need thereof; wherein said HMM is dissolved in an aqueous emulsion comprising about 2-20% of an edible oil; about 0.1-7% of a phosphatide and about 1-10% glycerol, so that peripheral neuropathy is reduced from that observed when the same amount of HMM is orally administered.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein the pH of the HMM solution is about 4.5-6.0.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein about 500-600 mg/m 2 /day of HMM is administered.
Claim 5
Dependent Claim
24 words
The method of claim 3 wherein the HMM is administered in conjunction with an effective amount of cisplatin, cyclosphosphamide, doxorubicin, vinca alkaloids or etoposide.
Claim 6
Dependent Claim
12 words
The method of claim 1 wherein the edible oil comprises soybean oil.
Claim 7
Dependent Claim
12 words
The method of claim 1 wherein the phosphatide comprises egg yolk phospholipids.
Claim 8
Dependent Claim
14 words
The method of claim 1 wherein the HMM solution comprises about 1-6 mg/ml HMM.
References Cited (Backward Citations)
US32393A
Cited
US4784845A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-04-01 | 1994-10-01 | 1995-04-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-04-01 | 1998-10-01 | 1999-04-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-04-01 | 2002-10-01 | 2003-04-02 | $7700.00 | Window Closed / Lapsed |